FilingReader Intelligence

King-Friend Biochemical Pharmaceutical updates on bonds, share repurchases

October 9, 2025 at 08:59 AM UTCBy FilingReader AI

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. announced that as of September 30, 2025, RMB 719,000 of its "King-Friend convertible bonds" had been converted into ordinary shares, totaling 18,035 shares, representing 0.001% of the company's pre-conversion share capital. Additionally, RMB 7,000 of the convertible bonds were repurchased. The remaining unconverted "King-Friend convertible bonds" amount to RMB 502,464,000, or 99.86% of the total issuance. The company's total share capital remained unchanged at 1,615,634,969 shares between July 1 and September 30, 2025.

In a separate announcement, the company provided an update on its share repurchase program. As of September 30, 2025, King-Friend Biochemical Pharmaceutical had cumulatively repurchased 880,000 shares through the Shanghai Stock Exchange, accounting for 0.05% of its total share capital. The repurchases were executed at prices ranging from RMB 11.58 to RMB 11.66 per share, with a total expenditure of RMB 10,220,700 (excluding transaction costs and stamp duty).

The ongoing share repurchase program, approved in April and May 2025, aims to repurchase between RMB 20,000,000 and RMB 40,000,000 worth of shares at a maximum price of RMB 18.75 per share. These repurchased shares are intended for employee stock ownership plans or equity incentive programs, with the program's duration extending 12 months from the shareholder approval date.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Nanjing King-Friend Biochemical Pharmaceutical publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →